Vaccines to prevent infections by oncoviruses

Annual Review of Microbiology

Volumn 64, Issue , 2010, Pages 23-41

  Schiller, John T ^a   Lowy, Douglas R ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

EBV; HBV; HCV; HPV; HTLV; KSHV

Indexed keywords

EPSTEIN BARR VIRUS VACCINE; HEPATITIS B VACCINE; HEPATITIS C VACCINE; HUMAN HERPESVIRUS 8 VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE; WART VIRUS VACCINE;

EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HERPES VIRUS INFECTION; HUMAN; HUMAN HERPESVIRUS 8; HUMAN HERPESVIRUS 8 INFECTION; IMMUNIZATION; NEOPLASM; NONHUMAN; ONCOVIRINAE; PRIORITY JOURNAL; REVIEW; VERRUCA VULGARIS; WART VIRUS;

EPSTEIN-BARR VIRUS INFECTIONS; HEPACIVIRUS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 4, HUMAN; HERPESVIRUS 8, HUMAN; HUMANS; NEOPLASMS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; RETROVIRIDAE; VIRAL VACCINES;

HEPATITIS B VIRUS; HEPATITIS C VIRUS; HERPESVIRIDAE; HUMAN HERPESVIRUS 4; HUMAN HERPESVIRUS 8; HUMAN PAPILLOMAVIRUS; HUMAN T-LYMPHOTROPIC VIRUS 1;

EID: 77956385180     PISSN: 00664227     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.micro.112408.134019     Document Type: Review

References (87)

1. Adhikary D, Behrends U, Feederle R, Delecluse HJ, Mautner J. 2008. Standardized and highly efficient expansion of Epstein-Barr virus-specific CD4+ T cells by using virus-like particles. J. Virol. 82:3903-11
2. Areste C, Blackbourn DJ. 2009. Modulation of the immune system by Kaposi's sarcoma-associated her-pesvirus. Trends Microbiol. 17:119-29
3. Barillari G, Ensoli B. 2002. Angiogenic effects of extracellular human immunodeficiency virus type 1 Tat protein and its role in the pathogenesis of AIDS-associated Kaposi's sarcoma. Clin. Microbiol. Rev. 15:310-26
4. Bartosch B, Dubuisson J, Cosset FL. 2003. Infectious hepatitis C virus pseudoparticles containing functional E1-E2 envelope protein complexes. J. Exp. Med. 197:633-42
5. Baseman JG, Koutsky LA. 2005. The epidemiology of human papillomavirus infections. J. Clin. Virol. 32(Suppl. 1):S16-24
6. Beasley RP, Hwang LY, Lin CC, Chien CS. 1981. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22,707 men in Taiwan. Lancet 2:1129-33
7. Bosch FX, Burchell AN, Schiffman M, Giuliano AR, de Sanjose S, et al. 2008. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 26(Suppl. 10):K1-16
8. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. 2002. The causal relation between human papil-lomavirus and cervical cancer. J. Clin. Pathol. 55:244-65
9. Bosch FX, Ribes J, Cleries R, Diaz M. 2005. Epidemiology of hepatocellular carcinoma. Clin. Liver Dis. 9:191-211
10. Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, et al. 2009. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J. Infect. Dis. 199:926-35
11. Cantarella G, Liniger M, Zuniga A, Schiller JT, Billeter M, et al. 2009. Recombinant measles virus-HPV vaccine candidates for prevention of cervical carcinoma. Vaccine 27:3385-90
12. Chang MH, Chen CJ, Lai MS, Hsu HM,Wu TC,etal. 1997. Universal hepatitisB vaccination inTaiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N. Engl. J. Med. 336:1855-59
13. Chang MH, You SL, Chen CJ, Liu CJ, Lee CM, et al. 2009. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J. Natl. Cancer Inst. 101:1348-55
14. Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, et al. 1994. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 266:1865-69
15. Chisari FV, Ferrari C. 1995. Hepatitis B virus immunopathogenesis. Annu. Rev. Immunol. 13:29-60
16. Chotiyaputta W, Lok AS. 2009. Hepatitis B virus variants. Nat. Rev. Gastroenterol. Hepatol. 6:453-62
17. David MP, Van Herck K, Hardt K, Tibaldi F, Dubin G, et al. 2009. Long-term persistence of anti-HPV-16 and-18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses. Gynecol. Oncol. 115:S1-6
18. Delecluse HJ, Feederle R, Behrends U, Mautner J. 2008. Contribution of viral recombinants to the study of the immune response against the Epstein-Barr virus. Semin. Cancer Biol. 18:409-15
19. Demberg T, Robert-Guroff M. 2009. Mucosal immunity and protection against HIV/SIV infection: strategies and challenges for vaccine design. Int. Rev. Immunol. 28:20-48
20. Durst M, Gissmann L, Ikenberg H, zur Hausen H. 1983. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc. Natl. Acad. Sci. USA 80:3812-15
21. Dustin LB, Rice CM. 2007. Flying under the radar: the immunobiology of hepatitis C. Annu. Rev. Immunol. 25:71-99
22. Edmunds WJ, Medley GF, Nokes DJ, Hall AJ, Whittle HC. 1993. The influence of age on the development of the hepatitis B carrier state. Proc. Biol. Sci. 253:197-201
23. Elliott SL, Suhrbier A, Miles JJ, Lawrence G, Pye SJ, et al. 2008. Phase I trial of a CD8+ T-cell peptide epitope-based vaccine for infectious mononucleosis. J. Virol. 82:1448-57
24. Engels EA, Biggar RJ, Hall HI, Cross H, Crutchfield A, et al. 2008. Cancer risk in people infected with human immunodeficiency virus in the United States. Int. J. Cancer 123:187-94
25. Epstein MA, Achong BG, Barr YM. 1964. Virus particles in cultured lymphoblasts from Burkitt's lym-phoma. Lancet 1:702-3
26. Feinstone SM, Kapikian AZ, Purcell RH, Alter HJ, Holland PV. 1975. Transfusion-associated hepatitis not due to viral hepatitis type A or B. N. Engl. J. Med. 292:767-70
27. Feng H, Shuda M, Chang Y, Moore PS. 2008. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 319:1096-100
28. Fraillery D, Baud D, Pang SY, Schiller J, Bobst M, et al. 2007. Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever. Clin. Vaccine Immunol. 14:1285-95
29. Ganem D. 2006. KSHV infection and the pathogenesis of Kaposi's sarcoma. Annu. Rev. Pathol. 1:273-96
30. Ganem D. 2007. Kaposi's sarcoma-associated herpesvirus. See Ref. 48, pp. 2847-88
31. Gillison ML, Chaturvedi AK, Lowy DR. 2008. HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer 113:3036-46
32. Goldstein ST, Zhou F, Hadler SC, Bell BP, Mast EE, Margolis HS. 2005. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int. J. Epidemiol. 34:1329-39
33. Goon PK, Biancardi A, Fast N, Igakura T, Hanon E, et al. 2004. Human T cell lymphotropic virus (HTLV) type-1-specific CD8+ T cells: frequency and immunodominance hierarchy. J. Infect. Dis. 189:2294-98
34. Hino S, Katamine S, Miyata H, Tsuji Y, Yamabe T, Miyamoto T. 1997. Primary prevention of HTLV-1 in Japan. Leukemia 11(Suppl. 3):57-59
35. Hinuma Y, Nagata K, Hanaoka M, Nakai M, Matsumoto T, et al. 1981. Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc. Natl. Acad. Sci. USA 78:6476-80
36. Houghton M, Abrignani S. 2005. Prospects for a vaccine against the hepatitis C virus. Nature 436:961-66
37. Howley PM, Lowy DR. 2007. Pappillomaviruses. See Ref. 48, pp. 2299-354
38. Jagu S, Karanam B, Gambhira R, Chivukula SV, Chaganti RJ, et al. 2009. Concatenated multitype L2 fusion proteinsascandidate prophylactic pan-human papillomavirus vaccines.J. Natl. Cancer Inst. 101:782-92
39. Jia Q, Freeman ML, Yager EJ, McHardy I, Tong L, et al. 2010. Induction of protective immunity against murine gammaherpesvirus 68 infection in the absence of viral latency. J. Virol. 84:2453-65
40. Kannagi M, Harashima N, Kurihara K, Ohashi T, Utsunomiya A, et al. 2005. Tumor immunity against adult T-cell leukemia. Cancer Sci. 96:249-55
41. Kanodia S, Da Silva DM, Kast WM. 2008. Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions. Int. J. Cancer 122:247-59
42. Kato T, Date T, Miyamoto M, Furusaka A, Tokushige K, et al. 2003. Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon. Gastroenterology 125:1808-17
43. Khanna R, Moss DJ, Burrows SR. 1999. Vaccine strategies against Epstein-Barr virus-associated diseases: lessons from studies on cytotoxic T-cell-mediated immune regulation. Immunol. Rev. 170:49-64
44. Kines RC, Thompson CD, Lowy DR, Schiller JT, Day PM. 2009. The initial steps leading to papillo-mavirus infection occur on the basement membrane prior to cell surface binding. Proc. Natl. Acad. Sci. USA 106:20458-63
45. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. 1992. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc. Natl. Acad. Sci. USA 89:12180-84
46. Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, et al. 2009. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev. Res. 2:868-78
47. Klein E, Kis LL, Klein G. 2007. Epstein-Barr virus infection in humans: from harmless to life endangering virus-lymphocyte interactions. Oncogene 26:1297-305
48. Knipe DM, Howley PM, eds. 2007. Field's Virology. Philadelphia Lippincott Williams & Wilkins.
49. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, et al. 2002. A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. 347:1645-51
50. Kutok JL, Wang F. 2006. Spectrum of Epstein-Barr virus-associated diseases. Annu. Rev. Pathol. 1:375-404
51. Latirmore MD, Franchini G. 2007. Human T-cell leukemia types 1 and 2. See Ref. 48, pp. 2071-105
52. Levy-Bruhl D, Bousquet V, King LA, O'Flanagan D, Bacci S, et al. 2009. The current state of introduction of HPV vaccination into national immunization schedules in Europe: results of the VENICE 2008 survey. Eur. J. Cancer 45:2709-13
53. Liang TJ. 2009. Hepatitis B: the virus and disease. Hepatology 49:S13-21
54. Lockey TD, Zhan X, Surman S, Sample CE, Hurwitz JL. 2008. Epstein-Barr virus vaccine development: a lytic and latent protein cocktail. Front. Biosci. 13:5916-27
55. Lowy DR, Solomon D, Hildesheim A, Schiller JT, Schiffman M. 2008. Human papillomavirus infection and the primary and secondary prevention of cervical cancer. Cancer 113:1980-93
56. Lupberger J, Hildt E. 2007. Hepatitis B virus-induced oncogenesis. World J. Gastroenterol. 13:74-81
57. Lynch MP, Kaumaya PT. 2006. Advances in HTLV-1 peptide vaccines and therapeutics. Curr. Protein Pept. Sci. 7:137-45
58. Mast EE, Ward JW. 2004. Hepatitis B vaccines. In Vaccines, ed. SA Plotkin, WA Orenstei, PA Offit, pp. 205-42. Maryland Heights, MO: Saunders. 5th ed.
59. Maynard JE. 1978. Passive immunization against hepatitis B: a review of recent studies and comment on current aspects of control. Am. J. Epidemiol. 107:77-86
60. McAleer WJ, Buynak EB, Maigetter RZ, Wampler DE, Miller WJ, Hilleman MR. 1984. Human hepatitis B vaccine from recombinant yeast. Nature 307:178-80
61. Munz C, Moormann A. 2008. Immune escape by Epstein-Barr virus associated malignancies. Semin. Cancer Biol. 18:381-87
62. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, et al. 2009. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374:301-14
63. Parkin DM. 2006. The global health burden of infection-associated cancers in the year 2002. Int. J. Cancer 118:3030-44
64. Pestka JM, Zeisel MB, Blaser E, Schurmann P, Bartosch B, et al. 2007. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc. Natl. Acad. Sci. USA 104:6025-30
65. Pica F, Volpi A. 2007. Transmission of human herpesvirus 8: an update. Curr. Opin. Infect. Dis. 20:152-56
66. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. 1980. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc. Natl. Acad. Sci. USA 77:7415-19
67. Poovorawan Y, Chongsrisawat V, Theamboonlers A, Bock HL, Leyssen M, Jacquet JM. 2010. Persistence of antibodies and immune memory to hepatitis B vaccine 20 years after infant vaccination in Thailand. Vaccine 28:730-36
68. Richardson AB, Kieff E. 2007. Epstein-Barr virus. See Ref. 48, pp. 2655-700
69. Roberts JN, Buck CB, Thompson CD, Kines R, Bernardo M, et al. 2007. Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat. Med. 13:857-61
70. Savoldo B, Goss JA, Hammer MM, Zhang L, Lopez T, et al. 2006. Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood 108:2942-49
71. Schiller JT, Castellsague X, Villa L, Hildesheim A. 2008. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine 26S:K53-61
72. Schiller JT, Lowy DR. 2009. Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials. J. Infect. Dis. 200:166-71
73. Shefer A,Markowitz L, Deeks S, Tam T, Irwin K,et al. 2008. Early experience with human papillomavirus vaccine introduction in the United States, Canada and Australia. Vaccine 26(Suppl. 10):K68-75
74. Shepard CW, Finelli L, Alter MJ. 2005. Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis. 5:558-67
75. Sokal EM, Hoppenbrouwers K, Vandermeulen C, Moutschen M, Leonard P, et al. 2007. Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults. J. Infect. Dis. 196:1749-53
76. Stamatatos L, Morris L, Burton DR, Mascola JR. 2009. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat. Med. 15:866-70
77. Stoll-Keller F, Barth H, Fafi-Kremer S, Zeisel MB, Baumert TF. 2009. Development of hepatitis C virus vaccines: challenges and progress. Expert Rev. Vaccines 8:333-45
78. Strowig T, Gurer C, Ploss A, Liu YF, Arrey F, et al. 2009. Priming of protective T cell responses against virus-induced tumors in mice with human immune system components. J. Exp. Med. 206:1423-34
79. Sullivan RJ, Pantanowitz L, Casper C, Stebbing J, Dezube BJ. 2008. HIV/AIDS: epidemiology, patho-physiology, and treatment of Kaposi sarcoma-associated herpesvirus disease: Kaposi sarcoma, primary effusion lymphoma, and multicentric Castleman disease. Clin. Infect. Dis. 47:1209-15
80. Sullivan RJ, Pantanowitz L, Dezube BJ. 2009. Targeted therapy for Kaposi sarcoma. BioDrugs 23:69-75
81. ?0201 restricted cytotoxic T-lymphocyte peptide construct against challenge with human T-cell lymphotropic virus type 1 Tax recombinant vaccinia virus. J. Acquir. Immune Defic. Syndr. 37:1329-39
82. Tajima K. 1990. The fourth nation-wide study of adult T-cell leukemia/lymphoma (ATL) in Japan: estimates of risk of ATL and its geographical and clinical features. The T-and B-cell Malignancy Study Group. Int. J. Cancer 45:237-43
83. Tang H, Grise H. 2009. Cellular and molecular biology of HCV infection and hepatitis. Clin. Sci. 117:49-65
84. Urisman A, Molinaro RJ, Fischer N, Plummer SJ, Casey G, et al. 2006. Identification of a novel Gam-maretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant. PLoS Pathog. 2:e25
85. Westmoreland SV, Mansfield KG. 2008. Comparative pathobiology of Kaposi sarcoma-associated her-pesvirus and related primate rhadinoviruses. Comp. Med. 58:31-42
86. Zanetti AR, Van Damme P, Shouval D. 2008. The global impact of vaccination against hepatitis B: a historical overview. Vaccine 26:6266-73
87. Zhang P, Zhong L, Struble EB, Watanabe H, Kachko A, et al. 2009. Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activity. Proc. Natl. Acad. Sci. USA 106:7537-41